Klotho Neurosciences, Inc. Warrant (KLTOW)

• 1 day: 0.00%
• 5 days: 9.25%
• 1 month: -20.93%
• 3 months: 591.06%
• 6 months: 389.91%
• Year to date: 239.32%
• 1 year: 264.81%
• 5 years: 21.43%
• 10 years: 21.43%
• Sector: Healthcare
• Industry: Biotechnology

About: Klotho Neurosciences Inc is in the development of essential medicines for the treatment of chronic diseases: Cancer, Cardiovascular, and Neurodegenerative disorders. The Company currently has acquired two licensed platforms: a generic drug portfolio and a biosimilar biologics platform that uses biologic therapies to treat cancer, and a proprietary, patented gene therapy platform which uses a gene therapy approach to introduce a therapeutic protein called Klotho inside the body to treat neurodegenerative diseases. Company pipeline includes KLTO 101, KLTO 202, KLTO 301.

Employees: 3

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

200% more repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 1

96% more capital invested

Capital invested by funds: $285K [Q1] → $559K (+$274K) [Q2]

63% less funds holding

Funds holding: 19 [Q1] → 7 (-12) [Q2]

86% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 14